Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Immunovant (NASDAQ:IMVT) and raised the price target from $27 to $33.
July 24, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunovant's price target has been raised from $27 to $33 by Wells Fargo, maintaining an Overweight rating.
The raised price target and maintained Overweight rating by Wells Fargo indicates a positive outlook for Immunovant. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100